Market CapAU$24m

Last Close AU$0.16

Exopharm is a drug delivery technology company that has a suite of technology for the development of extracellular vesicle (EV) based therapeutics. It has developed/licensed three technologies EVPS, LOAD, and LEAP for the targeting, loading, and purification of EVs respectively. Its primary shorter-term goal is to out-license these technologies to a number of major drug developers and biomanufacturing companies.

More Exopharm content >

Investment summary

We are initiating research on Exopharm, a company focused on providing solutions for the development of targeted therapeutics using extracellular vesicles (EVs). EVs are small packets of material naturally released by cells in the body that are being investigated for their therapeutic properties and for improving drug delivery, and Exopharm has a suite of technology that may be useful for the development and manufacture of EV therapeutics. Its goal is to out-license this platform to one or more major pharmaceutical partners for the development of EV-based drugs.

Content on Exopharm
Exopharm – All the parts for drug delivery development
Healthcare | research Initiation | 28 May 2021
Cells secreting exosomes
Exopharm – Edison Open House interview
Healthcare | Edison TV | 26 January 2021
View more
Register to receive research on Exopharm as it is published
Share price graph
Price performance
Actual (38.0) (58.1) (77.0)
Relative* (34.0) (57.5) (77.5)
52-week high/low A$0.7/A$0.2
*% relative to local index
Key management
Dr Chris Baldwin COO
Ian Dixon MD and founder